Stock Traders Buy Large Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw some unusual options trading activity on Wednesday. Investors purchased 252,816 call options on the stock. This is an increase of 77% compared to the typical daily volume of 143,026 call options.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: FDA begins a formal review to consider whether multiple peptide bulk drug substances can be used by compounding pharmacies — a change that could expand addressable market for telehealth sellers like Hims & Hers. Article Title
• Positive Sentiment: Comments from FDA leadership (and coverage noting RFK Jr.’s stance) signaled a regulatory pivot toward loosening peptide restrictions, boosting investor confidence in a policy-driven growth leg. Article Title
• Positive Sentiment: Bank of America raised its price target to $25 (Neutral rating) citing the FDA step as an early-stage catalyst that could meaningfully boost peptide revenue if regulatory changes proceed. Article Title
• Neutral Sentiment: Reuters and other outlets frame the move as a potential long?term win but emphasize this is an early, advisory-stage process (PCAC meetings scheduled for July 23–24). Timing and final regulatory outcomes remain uncertain. Article Title
• Neutral Sentiment: Unusually large call-option activity was recorded recently, indicating elevated speculative interest and positioning around the regulatory story (high short?term gamma/volatility risk).
• Negative Sentiment: Several analyst pieces note HIMS’ recent operational strains — the stock is down materially over six months, with margins and cash flow under pressure — which could blunt upside if peptide approval is delayed or narrower than hoped. Article Title

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and upped their price objective for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Bank of America upped their price objective on shares of Hims & Hers Health from $21.00 to $25.00 and gave the company a “neutral” rating in a research note on Thursday. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $31.86.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $27.06 on Friday. The company has a fifty day moving average of $19.60 and a 200-day moving average of $32.66. The firm has a market capitalization of $6.17 billion, a P/E ratio of 53.05, a P/E/G ratio of 2.31 and a beta of 2.32. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.11 EPS. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the sale, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 129,889 shares of company stock valued at $3,230,986. Company insiders own 13.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Capital World Investors increased its stake in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. State Street Corp grew its position in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after purchasing an additional 132,311 shares during the period. Finally, Geode Capital Management LLC grew its position in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.